News

Cadence Adds New Class 7 (10,000) Cleanroom in Connecticut

Cadence, Inc., a leading contract manufacturer of medical devices, announced today the completion of a certified International Organization for Standardization (ISO) Class 7 (10,000) cleanroom at its Connecticut manufacturing facility.  The new cleanroom is dedicated to the production of innovative medical device components and subassemblies.

“The cleanroom opens the door to new, exciting opportunities for our manufacturing facility,” stated Chris Haddad, the Director of Operations at Cadence’s Connecticut facility.  “Adding the new cleanroom and citric passivation allows us to expand our service offerings for existing and new customers, as well as streamlines our supply chain, reduces costs, and complements our laser processing expertise.”

The new cleanroom further enhances Cadence’s portfolio as a leading, vertically integrated contract manufacturing partner of medical devices worldwide.  Cadence now offers certified cleanroom manufacturing at three of its facilities for maximum customer flexibility.

Located in Suffield, the Connecticut facility is dedicated to advanced laser processing technologies.  Virtually tour Cadence’s Connecticut facility here.

Read more here.

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns